New developments in the treatment of HER2-positive breast cancer
about
Engineering of bispecific affinity proteins with high affinity for ERBB2 and adaptable binding to albuminArtemin, a member of the glial cell line-derived neurotrophic factor family of ligands, is HER2-regulated and mediates acquired trastuzumab resistance by promoting cancer stem cell-like behavior in mammary carcinoma cells.The Potential of panHER Inhibition in Cancer.
P2860
New developments in the treatment of HER2-positive breast cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
New developments in the treatment of HER2-positive breast cancer
@en
New developments in the treatment of HER2-positive breast cancer.
@nl
type
label
New developments in the treatment of HER2-positive breast cancer
@en
New developments in the treatment of HER2-positive breast cancer.
@nl
prefLabel
New developments in the treatment of HER2-positive breast cancer
@en
New developments in the treatment of HER2-positive breast cancer.
@nl
P2860
P356
P1476
New developments in the treatment of HER2-positive breast cancer
@en
P2093
Rita Nahta
P2860
P356
10.2147/BCTT.S24976
P577
2012-05-01T00:00:00Z